BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026.
The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases. The ADDRESS-LC study is evaluating whether bezisterim can improve neurological symptoms associated with Long COVID, including cognitive impairment and fatigue.
Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) announced that it has completed drilling the 183-H2 well at its 100%-owned Murucututu natural gas field in Brazil.
The well reached a total measured depth of 3,176.5 metres and was drilled within an area assigned prospective resources by independent reserve evaluator GLJ.
TNR Gold Corp (TSX-V:TNR, FRA:TNW, OTC:TRRXF) has launched its 2026 exploration program at the Shotgun Gold Project in southwestern Alaska, advancing work at the Shotgun and Winchester prospects in the Taylor Mountain Quadrangle.
The program builds on 2022 fieldwork and will follow up on geochemical anomalies identified through Novagold Resources' 1998 soil surveys, along with geophysical targets flagged by SJ Geophysics' 2011 and 2012 IP surveys.
PG&E Corp (NYSE:PCG) shares fell more than 19% after California lawmakers advanced wildfire legislation that stopped short of the liability protections utility investors had been seeking.
The amended Senate Bill 492 excludes a proposal from Governor Gavin Newsom that would have blocked insurance companies from suing utilities over wildfire-related claims, raising fresh concerns about Pacific Gas and Electric Company's exposure to future disasters.
Aon PLC (NYSE:AON) has agreed to acquire insurance brokerage USI from KKR for $17 billion including debt, the companies said Monday, as Aon expands its reach among medium-sized businesses.
USI provides risk management, health insurance and retirement plan services for businesses and individuals, and reports about $3 billion in annual revenue.
Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases.
The acquisition continues a run of dealmaking for Lilly, whose deal spending this year has outpaced prior years as it looks to diversify beyond its blockbuster obesity and diabetes franchises.